Androgen deprivation treatment

Phase 3Small molecule

Androgen deprivation treatment is one of 75 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerActive, not recruiting

Prostate CancerNot yet recruiting

Metastatic Prostate CancerPreclinical

Active, not recruiting

Prostate CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

20 2

Talzenna

Pfizer

Phase 3

7 3

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 4

LHRH Agonist

Roche

Phase 3

10 5

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Phase 3

4 6

Semaglutide Pen Injector

UUniversitaire Ziekenhuizen KU Leuven

Phase 3

1 7

Androgen deprivation treatment

MMedical University of Vienna

Phase 3

1 8

Rhpsma-7.3 (18f)

BBlue Earth Diagnostics

Phase 3

4 9

Trexall

Jazz Pharmaceuticals

Preclinical

—10

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Not yet recruiting

Prostate Cancer

NCT06861166

Q4 2031

Not yet recruiting

Metastatic Prostate Cancer

NCT06430411

Clinical

Trials by Indication[1]

Metastatic Prostate Cancer1 trial

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study

Not yet recruiting·MMedical University of Vienna··NCT06430411·500 enrolled

Prostate Cancer1 trial

Clinical Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

Not yet recruiting·Bbaotai Liang·Phase 2/3·NCT06861166·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Androgen deprivation treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Androgen deprivation treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Androgen deprivation treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Vienna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedical University of Vienna

Androgen deprivation treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2031

Trials by Indication[1]

Metastatic Prostate Cancer1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News